Related Experiment Video
Updated: Sep 19, 2025

Electrode Positioning and Montage in Transcranial Direct Current Stimulation
Published on: May 23, 2011
Analgesic aftereffects of alpha high-definition transcranial alternating current stimulation over the DLPFC during
Baijintao Sun1, Chuan Zhang2, Qingwei Zhang3
1Science and Technology and Innovation Center, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan Province, 637000, China; Biotechnology Innovation Drug Application and Transformation Key Laboratory of Sichuan Province, North Sichuan Medical College, Nanchong, Sichuan Province 637000, China.
Abstract:
High-definition transcranial alternating current stimulation (HD-tACS) targeting the dorsolateral prefrontal cortex (DLPFC) holds promise for pain management, though its neurobiological mechanisms remain unclear. This study aimed to investigate whether alpha HD-tACS applied to the left DLPFC modulates gamma oscillations to sustain analgesia during capsaicin-induced experimental pain (0.1% Capsaicin cream). Forty-five healthy participants underwent a single-blind, within-subject, sham-controlled protocol. EEG recordings were taken at three key time points: baseline (resting state), 5 minutes post-HD-tACS, and 15 minutes post-HD-tACS. Numeric rating scale (NRS) and oscillatory power changes were analyzed before, during, and after both active and sham stimulation. Results showed that active alpha HD-tACS significantly reduced NRS and area under curve (AUC) scores during both the stimulation period (0-30 minutes) and the post-stimulation period (30-60 minutes) compared to sham. EEG analyses revealed increased theta (4-7 Hz), alpha (8-13 Hz), beta(14-29 Hz), and low gamma (30-55 Hz) oscillations in the left DLPFC post-stimulation, but only low gamma oscillations passed the false discovery rate (FDR) correction. These findings suggest that alpha HD-tACS induces delayed analgesia by modulating low gamma oscillations in the DLPFC, highlighting its potential as a tool for optimizing non-invasive neuromodulation in pain therapy. The study bridges mechanistic insights with clinical outcomes, emphasizing the role of DLPFC low gamma activity in maintaining endogenous pain control.

